NCT02947854View on ClinicalTrials.gov

Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant

PHASE1CompletedINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

March 26, 2018

Study Completion Date

March 26, 2018

Conditions
Healthy Volunteer
Interventions
DRUG

Fimaporfin (Photosensitizer)

BIOLOGICAL

Hiltonol (Poly-ICLC)

BIOLOGICAL

HPV E7 (Human Papilloma Virus E7) peptides

BIOLOGICAL

KLH (Keyhole Limpet Hemocyanin)

Trial Locations (1)

LS29LH

Covance Clinical Research Unit Limited, Leeds

Sponsors

Lead Sponsor

PCI Biotech AS
All Listed Sponsors
lead

PCI Biotech AS

INDUSTRY